Product Code: TMRGL86112
Cardiac Troponin Market - Scope of Report
TMR's report on the global cardiac troponin market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global cardiac troponin market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cardiac troponin market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cardiac troponin market.
Market Snapshot |
Market Value in 2023 | US$ 4.5 Bn |
Market Value in 2034 | US$ 11.5 Bn |
CAGR | 8.9% |
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cardiac troponin market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cardiac troponin market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cardiac troponin market.
The report delves into the competitive landscape of the global cardiac troponin market. Key players operating in the global cardiac troponin market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cardiac troponin market profiled in this report.
Key Questions Answered in Global cardiac troponin Market Report:
- What is the sales/revenue generated by cardiac troponin across all regions during the forecast period?
- What are the opportunities in the global cardiac troponin market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2034?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Cardiac Troponin Market - Research Objectives and Research Approach
The comprehensive report on the global cardiac troponin market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global cardiac troponin market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cardiac troponin market.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiac Troponin Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution / Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Cardiac Troponin Market Analysis and Forecast, 2020-2034
5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Key Product/Brand Analysis
- 5.3. Key Mergers & Acquisitions
- 5.4. COVID-19 Pandemic Impact on Industry
6. Global Cardiac Troponin Market Analysis and Forecast, by Troponin Type
- 6.1. Introduction and Definitions
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Troponin Type, 2020-2034
- 6.3.1. Troponin I
- 6.3.2. Troponin T
- 6.3.3. Troponin C
- 6.4. Market Attractiveness, by Troponin Type
7. Global Cardiac Troponin Market Analysis and Forecast, by Setting
- 7.1. Introduction and Definitions
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Setting, 2020-2034
- 7.3.1. Laboratory Setting
- 7.3.2. Point-of-Care (POC) Testing
- 7.4. Market Attractiveness, by Setting
8. Global Cardiac Troponin Market Analysis and Forecast, by Indication
- 8.1. Introduction and Definitions
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by Indication, 2020-2034
- 8.3.1. Myocardial Infarction
- 8.3.2. Congestive Heart Failure
- 8.3.3. Acute Coronary Syndrome
- 8.3.4. Others (cardiomyopathy, etc.)
- 8.4. Market Attractiveness, by Indication
9. Global Cardiac Troponin Market Analysis and Forecast, by End-user
- 9.1. Introduction and Definitions
- 9.2. Key Findings/Developments
- 9.3. Market Value Forecast, by End-user, 2020-2034
- 9.3.1. Hospitals & Clinics
- 9.3.2. Diagnostic Laboratories
- 9.3.3. Homecare Settings
- 9.3.4. Others (Research Institutes, etc.)
- 9.4. Market Attractiveness, by End-user
10. Global Cardiac Troponin Market Analysis and Forecast, by Region
- 10.1. Key Findings
- 10.2. Market Value Forecast, by Region, 2020-2034
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
- 10.3. Market Attractiveness, by Region
11. North America Cardiac Troponin Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Market Value Forecast, by Troponin Type, 2020-2034
- 11.2.1. Troponin I
- 11.2.2. Troponin T
- 11.2.3. Troponin C
- 11.3. Market Attractiveness, by Troponin Type
- 11.4. Market Value Forecast, by Setting, 2020-2034
- 11.4.1. Laboratory Setting
- 11.4.2. Point-of-Care (POC) Testing
- 11.5. Market Attractiveness, by Setting
- 11.6. Market Value Forecast, by Indication, 2020-2034
- 11.6.1. Myocardial Infarction
- 11.6.2. Congestive Heart Failure
- 11.6.3. Acute Coronary Syndrome
- 11.6.4. Others (cardiomyopathy, etc.)
- 11.7. Market Attractiveness, by Indication
- 11.8. Market Value Forecast, by End-user, 2020-2034
- 11.8.1. Hospitals & Clinics
- 11.8.2. Diagnostic Laboratories
- 11.8.3. Homecare Settings
- 11.8.4. Others (Research Institutes, etc.)
- 11.9. Market Attractiveness, by End-user
- 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
- 11.10.1. U.S.
- 11.10.2. Canada
- 11.11. Market Attractiveness Analysis
- 11.11.1. By Troponin Type
- 11.11.2. By Setting
- 11.11.3. By Indication
- 11.11.4. By End-user
- 11.11.5. By Country
12. Europe Cardiac Troponin Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Market Value Forecast, by Troponin Type, 2020-2034
- 12.2.1. Troponin I
- 12.2.2. Troponin T
- 12.2.3. Troponin C
- 12.3. Market Attractiveness, by Troponin Type
- 12.4. Market Value Forecast, by Setting, 2020-2034
- 12.4.1. Laboratory Setting
- 12.4.2. Point-of-Care (POC) Testing
- 12.5. Market Attractiveness, by Setting
- 12.6. Market Value Forecast, by Indication, 2020-2034
- 12.6.1. Myocardial Infarction
- 12.6.2. Congestive Heart Failure
- 12.6.3. Acute Coronary Syndrome
- 12.6.4. Others (cardiomyopathy, etc.)
- 12.7. Market Attractiveness, by Indication
- 12.8. Market Value Forecast, by End-user, 2020-2034
- 12.8.1. Hospitals & Clinics
- 12.8.2. Diagnostic Laboratories
- 12.8.3. Homecare Settings
- 12.8.4. Others (Research Institutes, etc.)
- 12.9. Market Attractiveness, by End-user
- 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
- 12.10.1. Germany
- 12.10.2. U.K.
- 12.10.3. France
- 12.10.4. Italy
- 12.10.5. Spain
- 12.10.6. Rest of Europe
- 12.11. Market Attractiveness Analysis
- 12.11.1. By Troponin Type
- 12.11.2. By Setting
- 12.11.3. By Indication
- 12.11.4. By End-user
- 12.11.5. By Country/Sub-region
13. Asia Pacific Cardiac Troponin Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Market Value Forecast, by Troponin Type, 2020-2034
- 13.2.1. Troponin I
- 13.2.2. Troponin T
- 13.2.3. Troponin C
- 13.3. Market Attractiveness, by Troponin Type
- 13.4. Market Value Forecast, by Setting, 2020-2034
- 13.4.1. Laboratory Setting
- 13.4.2. Point-of-Care (POC) Testing
- 13.5. Market Attractiveness, by Setting
- 13.6. Market Value Forecast, by Indication, 2020-2034
- 13.6.1. Myocardial Infarction
- 13.6.2. Congestive Heart Failure
- 13.6.3. Acute Coronary Syndrome
- 13.6.4. Others (cardiomyopathy, etc.)
- 13.7. Market Attractiveness, by Indication
- 13.8. Market Value Forecast, by End-user, 2020-2034
- 13.8.1. Hospitals & Clinics
- 13.8.2. Diagnostic Laboratories
- 13.8.3. Homecare Settings
- 13.8.4. Others (Research Institutes, etc.)
- 13.9. Market Attractiveness, by End-user
- 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
- 13.10.1. China
- 13.10.2. Japan
- 13.10.3. India
- 13.10.4. Australia & New Zealand
- 13.10.5. Rest of Asia Pacific
- 13.11. Market Attractiveness Analysis
- 13.11.1. By Troponin Type
- 13.11.2. By Setting
- 13.11.3. By Indication
- 13.11.4. By End-user
- 13.11.5. By Country/Sub-region
14. Latin America Cardiac Troponin Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Market Value Forecast, by Troponin Type, 2020-2034
- 14.2.1. Troponin I
- 14.2.2. Troponin T
- 14.2.3. Troponin C
- 14.3. Market Attractiveness, by Troponin Type
- 14.4. Market Value Forecast, by Setting, 2020-2034
- 14.4.1. Laboratory Setting
- 14.4.2. Point-of-Care (POC) Testing
- 14.5. Market Attractiveness, by Setting
- 14.6. Market Value Forecast, by Indication, 2020-2034
- 14.6.1. Myocardial Infarction
- 14.6.2. Congestive Heart Failure
- 14.6.3. Acute Coronary Syndrome
- 14.6.4. Others (cardiomyopathy, etc.)
- 14.7. Market Attractiveness, by Indication
- 14.8. Market Value Forecast, by End-user, 2020-2034
- 14.8.1. Hospitals & Clinics
- 14.8.2. Diagnostic Laboratories
- 14.8.3. Homecare Settings
- 14.8.4. Others (Research Institutes, etc.)
- 14.9. Market Attractiveness, by End-user
- 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
- 14.10.1. Brazil
- 14.10.2. Mexico
- 14.10.3. Rest of Latin America
- 14.11. Market Attractiveness Analysis
- 14.11.1. By Troponin Type
- 14.11.2. By Setting
- 14.11.3. By Indication
- 14.11.4. By End-user
- 14.11.5. By Country/Sub-region
15. Middle East & Africa Cardiac Troponin Market Analysis and Forecast
- 15.1. Introduction
- 15.2. Market Value Forecast, by Troponin Type, 2020-2034
- 15.2.1. Troponin I
- 15.2.2. Troponin T
- 15.2.3. Troponin C
- 15.3. Market Attractiveness, by Troponin Type
- 15.4. Market Value Forecast, by Setting, 2020-2034
- 15.4.1. Laboratory Setting
- 15.4.2. Point-of-Care (POC) Testing
- 15.5. Market Attractiveness, by Setting
- 15.6. Market Value Forecast, by Indication, 2020-2034
- 15.6.1. Myocardial Infarction
- 15.6.2. Congestive Heart Failure
- 15.6.3. Acute Coronary Syndrome
- 15.6.4. Others (cardiomyopathy, etc.)
- 15.7. Market Attractiveness, by Indication
- 15.8. Market Value Forecast, by End-user, 2020-2034
- 15.8.1. Hospitals & Clinics
- 15.8.2. Diagnostic Laboratories
- 15.8.3. Homecare Settings
- 15.8.4. Others (Research Institutes, etc.)
- 15.9. Market Attractiveness, by End-user
- 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
- 15.10.1. GCC Countries
- 15.10.2. South Africa
- 15.10.3. Rest of Middle East & Africa
- 15.11. Market Attractiveness Analysis
- 15.11.1. By Troponin Type
- 15.11.2. By Setting
- 15.11.3. By Indication
- 15.11.4. By End-user
- 15.11.5. By Country/Sub-region
16. Competition Landscape
- 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
- 16.2. Market Share Analysis, by Company (2023)
- 16.3. Company Profiles
- 16.3.1. F. Hoffmann-La Roche Ltd.
- 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.1.2. Product Portfolio
- 16.3.1.3. Financial Overview
- 16.3.1.4. SWOT Analysis
- 16.3.1.5. Strategic Overview
- 16.3.2. bioMerieux SA
- 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.2.2. Product Portfolio
- 16.3.2.3. Financial Overview
- 16.3.2.4. SWOT Analysis
- 16.3.2.5. Strategic Overview
- 16.3.3. Abbott Laboratories
- 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.3.2. Product Portfolio
- 16.3.3.3. Financial Overview
- 16.3.3.4. SWOT Analysis
- 16.3.3.5. Strategic Overview
- 16.3.4. Siemens Healthineers India
- 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.4.2. Product Portfolio
- 16.3.4.3. Financial Overview
- 16.3.4.4. SWOT Analysis
- 16.3.4.5. Strategic Overview
- 16.3.5. Eurolyser Diagnostica GmbH
- 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.5.2. Product Portfolio
- 16.3.5.3. Financial Overview
- 16.3.5.4. SWOT Analysis
- 16.3.5.5. Strategic Overview
- 16.3.6. QuidelOrtho Corporation
- 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.6.2. Product Portfolio
- 16.3.6.3. Financial Overview
- 16.3.6.4. SWOT Analysis
- 16.3.6.5. Strategic Overview
- 16.3.7. Beckman Coulter, Inc.
- 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.7.2. Product Portfolio
- 16.3.7.3. Financial Overview
- 16.3.7.4. SWOT Analysis
- 16.3.7.5. Strategic Overview
- 16.3.8. Response Biomedical Corporation
- 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.8.2. Product Portfolio
- 16.3.8.3. Financial Overview
- 16.3.8.4. SWOT Analysis
- 16.3.8.5. Strategic Overview
- 16.3.9. LifeSign LLC
- 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.9.2. Product Portfolio
- 16.3.9.3. Financial Overview
- 16.3.9.4. SWOT Analysis
- 16.3.9.5. Strategic Overview